Trial · NCT00775229
Naltrexone in the Treatment of Trichotillomania
NCT00775229, Phase 2, Completed, University of Chicago; results first posted 2014-03-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Naltrexone in the Treatment of Trichotillomania. Trials, record NCT00775229. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00775229
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Naltrexone in the Treatment of Trichotillomania
- NCT number
- NCT00775229
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 51 participants, actual
- Lead sponsor
- University of Chicago
- Conditions
- Trichotillomania
- Interventions
- Naltrexone, Placebo
- First posted
- 2008-10-20
- Last updated
- 2023-02-23
- Results first posted
- 2014-03-17
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | National Institute of Mental Health Trichotillomania Symptom Severity Scale | This is the final score, measured at week 8 (final visit). | Ranges from 0-20 with 20 being the most severe. The lower the total score, the lower the severity level. This scale is given and measured once every 2 weeks for a total of 8 weeks. The final total score is reported here. |
| Secondary | Massachusetts General Hospital Hairpulling Scale | This is the final score, measured at week 8 (final visit). | Ranges from 0-28 with 28 being the most severe. The lower the total score, the lower the severity level. This scale is given and measured once every 2 weeks for a total of 8 weeks. The final total score is reported here. |
| Secondary | Liver Function Tests | Week 8 (last visit) | Participants were administered a general test of liver functioning to asses safety over the course of the study. Data represent the percentage of participates with Liver Function Test values falling outside of the range considered safe/typical for liver functioning at any of the assessed time points. It was performed at baseline and at each visit where dosage of the medication is \>50mg/day (week 2-week 8). |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | National Institute of Mental Health Trichotillomania Symptom Severity Scale | This is the final score, measured at week 8 (final visit). | units on a scale | MEAN | |
| SECONDARY | Massachusetts General Hospital Hairpulling Scale | This is the final score, measured at week 8 (final visit). | units on a scale | MEAN | |
| SECONDARY | Liver Function Tests | Week 8 (last visit) | percentage of individuals with LFT chang | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| National Institute of Mental Health Trichotillomania Symptom Severity Scale | Naltrexone | 7.94 | Standard Deviation 4.835 | units on a scale | |
| National Institute of Mental Health Trichotillomania Symptom Severity Scale | Placebo | 8.73 | Standard Deviation 5.481 | units on a scale | |
| Massachusetts General Hospital Hairpulling Scale | Naltrexone | 12.21 | Standard Deviation 6.203 | units on a scale | |
| Massachusetts General Hospital Hairpulling Scale | Placebo | 13.35 | Standard Deviation 4.749 | units on a scale | |
| Liver Function Tests | Naltrexone | 0 | percentage of individuals with LFT chang | ||
| Liver Function Tests | Placebo | 0 | percentage of individuals with LFT chang |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Naltrexone | 25 | |
| Overall Study | STARTED | Placebo | 26 | |
| Overall Study | COMPLETED | Naltrexone | 20 | |
| Overall Study | COMPLETED | Placebo | 24 | |
| Overall Study | NOT COMPLETED | Naltrexone | 5 | |
| Overall Study | NOT COMPLETED | Placebo | 2 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Sedation | Psychiatric disorders | Naltrexone | 3 | 25 | 3 |
| other | Sedation | Psychiatric disorders | Placebo | 1 | 26 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Naltrexone | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Naltrexone | 3 | 25 |
| Total, other adverse events | Placebo | 1 | 26 |
| Total, serious adverse events | Naltrexone | 0 | 25 |
| Total, serious adverse events | Placebo | 0 | 26 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Naltrexone vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00775229
GET https://conductscience.org/api/trials/v1/NCT00775229/registered